News
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Eli Lilly’s GLP-1 pill helped some participants lose up to 15% body weight. But is it as effective as the injection? Here's ...
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, ...
2don MSN
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback